Impact Analysis of Covid-19
The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.
The Global Telmisartan Market, by Strength (20mg, 40mg, and 80mg), by Indication (Hypertension, Cardiac Arrest, and Stroke), By Composition (Single and Combinational), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) was valued at US$ 3,880.9 million in 2017 and is estimated to exhibit a CAGR of 1.4% over the forecast period (2018-2026) as highlighted in a new report published by Coherent Market Insights.
Get FREE Sample PDF Including COVID-19 Impact Analysis: https://www.coherentmarketinsights.com/insight/request-pdf/2524
Telmisartan is a prescription medication, which is often recommended to relax and widen blood vessels in persons with high blood pressure. Telmisartan belongs to a group of drugs known as angiotensin II receptor blockers (ARBs). Telmisartan may be used alone or in combination with other medications such as hydrochlorothiazide for treatment of high blood pressure.
The increasing awareness about hypertension and its management by organizing global campaigns are the factors that are expected to drive growth of the market over the forecast period. For instance, in May 2017, Argentinian Society of Hypertension (SAHA) participated in global campaigns such as ‘May Measurement Month and World Hypertension Day’ for creating awareness among population about blood pressure and its management.
Browse 23 Market Data Tables and 19 Figures spread through 157 Pages and in-depth TOC on ”Global Telmisartan Market” by Strength (20mg, 40mg, and 80mg), by Indication (Hypertension, Cardiac Arrest, and Stroke), by Composition (Single and Combinational), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) – Global Forecast to 2026″
To know the latest trends and insights related to Telmisartan market Press Release, click the link below: https://bit.ly/33QkAtM
Moreover, market players are focusing on product development and launches of new generic product to maximize access to end-users for their product in less cost, and these factors are expected to drive the market growth over the forecast period. For instance, in June 2017, Solco Healthcare received FDA approval for its Telmisartan tablets, 20mg, 40mg, and 80mg, which are AB-rated equivalents to Micardis by Boehringer Ingelheim. Solco Healthcare will market Telmisartan tablets in 30 count bottles for all three strengths.
In addition, rising number of government initiatives for hypertension management is further expected to drive growth of the global Telmisartan market. For instance, in December 2017, the Secretary, Ministry of Health and Family Welfare (MOHFW) and Secretary, Department of Health Research (DHR) and Director General, Indian Council of Medical Research (ICMR) launched, ‘India Hypertension Management Initiative (IHMI)’. The IHMI aims to reduce disability and death related to cardiovascular disease (CVD), by improving control over high blood pressure (hypertension), reducing salt consumption from food, and eliminating artificial trans-fats, which are leading risk factors for developing CVD.
Key Takeaways of the Telmisartan Market:
- The global telmisartan market is expected to exhibit a CAGR of 1.4% over the forecast period (2018-2026), attributed to continuous marketing approvals for telmisartan.
- Among strength, 80 mg segment is expected to hold dominant position in the global telmisartan market over the forecast period, attributed to approval from the U.S. FDA of telmisartan 80 mg in combination with other drugs. For instance, in September 2016, Nippon Boehringer Ingelheim Co., Ltd. and Astellas Pharma Inc. received the manufacturing and marketing approval for Micatrio combination tablets from the U.S. FDA. The tablet comprises telmisartan (concentration 80mg), amlodipine besylate, and hydrochlorothiazide (HCTZ). Such manufacturing and marketing approvals for telmisartan are expected to fuel the market growth over the forecast period.
- Key players operating in the global telmisartan market include C.H. Boehringer Sohn AG & Ko. KG, Glenmark Generics Inc., Torrent Pharmaceuticals Ltd., Solco Healthcare U.S., Mylan Inc., Aurobindo Pharma Limited, Yichang Changjiang Pharmaceutical Co., Ltd, Wanbang Biopharmaceuticals, and Nippon Boehringer Ingelheim Co., Ltd.
Apply Promo Code “STAYHOME” And Get an Instant Discount Of USD 1000
Buy Now This Premium Report to Grow your Business @ https://www.coherentmarketinsights.com/insight/buy-now/2524
About Us:
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
To know more about us, please visit our website – www.coherentmarketinsights.com
Contact:
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837
